Scholarlink

<p>Bladder cancer (BC), primarily urothelial carcinoma, remains one of the most common and lethal genitourinary malignancies worldwide, with limited long-term outcomes from standard treatments such as chemotherapy and radical cystectomy. These conventional modalities often fail to achieve durable responses and can severely affect patients’ quality of life, underscoring the need for more effective and targeted therapeutic strategies. Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte–associated protein 4 (CTsLA-4) have revolutionized BC therapy by restoring antitumor immune function. Nevertheless, treatment resistance, immune-related adverse events, and patient heterogeneity continue to limit their universal efficacy. This review provides an in-depth overview of ICI mechanisms and highlights evolving therapeutic approaches, including combination strategies with chemotherapy, radiotherapy, Bacillus Calmette–Guérin (BCG), and antibody–drug conjugates (ADCs). It also discusses emerging biomarkers such as <i>PD-L1</i> expression, tumor mutational burden (TMB), and DNA damage repair (DDR) deficiency as predictive tools for treatment selection. Overall, this study underscores the pivotal role of immunotherapy in reshaping bladder cancer management and outlines future directions toward safe, personalized, and biomarker-driven therapeutic paradigms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immune checkpoint inhibitors in bladder cancer: from mechanistic insights to emerging combination frontlines

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月5日

查看全文
  • Mohammad Mahdi Ajalli,
  • Yalda Sansebli,
  • Davood Ekrami,
  • Fatemeh Alaeenejad,
  • Ainaz Abbasi,
  • Pooya Eini,
  • Farnaz Hassanzadeh,
  • Nastaran Bahrami

摘要

Bladder cancer (BC), primarily urothelial carcinoma, remains one of the most common and lethal genitourinary malignancies worldwide, with limited long-term outcomes from standard treatments such as chemotherapy and radical cystectomy. These conventional modalities often fail to achieve durable responses and can severely affect patients’ quality of life, underscoring the need for more effective and targeted therapeutic strategies. Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte–associated protein 4 (CTsLA-4) have revolutionized BC therapy by restoring antitumor immune function. Nevertheless, treatment resistance, immune-related adverse events, and patient heterogeneity continue to limit their universal efficacy. This review provides an in-depth overview of ICI mechanisms and highlights evolving therapeutic approaches, including combination strategies with chemotherapy, radiotherapy, Bacillus Calmette–Guérin (BCG), and antibody–drug conjugates (ADCs). It also discusses emerging biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and DNA damage repair (DDR) deficiency as predictive tools for treatment selection. Overall, this study underscores the pivotal role of immunotherapy in reshaping bladder cancer management and outlines future directions toward safe, personalized, and biomarker-driven therapeutic paradigms.